Teknova achieved 33.2% gross margin in 2025, up 1,400 basis points from 2024
Revenue grew 7% to $40.5 million in 2025 with Q4 revenue reaching $10 million
Clinical Solutions revenue surged 47% year-over-year in Q4
Company projects path to Adjusted EBITDA breakeven by end of 2027
Teknova targets $42-44 million revenue guidance for 2026
📖 Full Retelling
Teknova Inc. (NASDAQ:TKNO) presented its fourth quarter and full year 2025 financial results on February 26, 2026, showcasing significant operational improvements including gross margins surging to 33% as the company marks its 30-year anniversary and works toward achieving profitability by late 2027. The life sciences reagent provider reported fourth quarter revenue of $10.0 million, representing 8% year-over-year growth and marking the company's sixth consecutive quarter of revenue expansion. This performance was primarily driven by a 47% surge in Clinical Solutions revenue to $2.7 million, while Lab Essentials remained flat at $6.8 million compared to the prior year. For the full year 2025, total revenue reached $40.5 million, up 7% from the prior year, supported by a diversified customer base of over 3,000 active accounts with a 95% retention rate. The most striking development was Teknova's dramatic improvement in gross margins, which reached 33.2% for the full year 2025, up 1,400 basis points from 19.2% in 2024. Management attributed this expansion to improved operational efficiency, better inventory management, and elimination of non-recurring charges related to expired and excess inventory that impacted 2024 results by $2.8 million. Looking ahead, Teknova provided revenue guidance of $42-44 million for 2026 and outlined a clear path to Adjusted EBITDA breakeven by the end of 2027, based on achieving annualized revenue of $52-57 million with approximately 70% contribution margins on incremental revenue.
Gross margin, or gross profit margin, is the difference between revenue and cost of goods sold (COGS), divided by revenue. Gross margin is expressed as a percentage. Generally, it is calculated as the selling price of an item, less the cost of goods sold (e.g., production or acquisition costs, not ...
Branches of science that involve the scientific study of life
This list of life sciences comprises the branches of science that involve the scientific study of life — such as animals (including human beings), microorganisms, and plants. This is one of the two major branches of natural science, the other being physical science, which is concerned with non-livin...
In economics, profit is the difference between revenue that an economic entity has received from its outputs and total costs of its inputs, also known as "surplus value". It is equal to total revenue minus total cost, including both explicit and implicit costs.
It is different from accounting profit...
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix declines to match Paramount Skydance bid for Warner Bros Dorsey’s Block slashes workforce 40% to embrace AI-native future, shares gain S&P 500, Nasdaq end in the red as Nvidia drags chip stocks lower Gold prices mixed as U.S.-Iran nuclear talks end after ’significant progress’ (South Africa Philippines Nigeria) Teknova Q4 2025 slides: gross margins surge to 33% on efficiency gains By Investing.com Company News Published 02/26/2026, 06:52 PM Teknova Q4 2025 slides: gross margins surge to 33% on efficiency gains 0 TKNO 0.89% Introduction & Market Context Alpha Teknova Inc. (NASDAQ:TKNO) presented its fourth quarter and full year 2025 financial results on February 26, 2026, showcasing significant operational improvements as the company marks its 30-year anniversary. The life sciences reagent provider demonstrated substantial margin expansion and continued revenue growth, though it remains on a path toward profitability with breakeven targeted for late 2027. The presentation comes as TKNO trades at $2.26, near its 52-week low of $1.91 and significantly below its 52-week high of $7.48, reflecting broader market skepticism about unprofitable life sciences companies despite operational progress. Quarterly Performance Highlights Teknova reported fourth quarter revenue of $10.0 million, representing 8% year-over-year growth and marking the company’s sixth consecutive quarter of revenue expansion. The performance was driven primarily by a 47% surge in Clinical Solutions revenue to $2.7 million, while Lab Essentials remained flat at $6.8 million compared to the prior year period. As shown in the following quarterly revenue breakdown, Clinical Solutions momentum accelerated significantly in the fourth quarter: For the full year 2025, total revenue reached $40.5 million, up 7% from the prior year. The company’s revenue composition reflects a diversified customer base of over 3,000 active accounts with a 95% retent...
